Literature DB >> 10728444

Vascular endothelial growth factor and hypertrophic osteoarthropathy.

L H Silveira1, M Martínez-Lavín, C Pineda, M C Fonseca, C Navarro, A Nava.   

Abstract

OBJECTIVE: Hypertrophic osteoarthropathy (HOA) is characterized by the coexistence of digital clubbing and periosteal proliferation of the tubular bones. Localized vascular proliferation associated with platelet/endothelial cell activation are recognized features of this syndrome. Current knowledge suggests that HOA develops from the presence in the systemic circulation of one or more growth factors that are normally inactivated in the lungs. The nature of these purported growth factors has not yet been identified. Vascular endothelial growth factor (VEGF) has several features that may fit in with the pathogenesis of HOA. The objective of our study was to measure serum and plasma levels of VEGF in different groups of patients with HOA.
METHODS: We studied 24 patients with HOA; of these, in 12 the HOA was secondary to cyanotic congenital heart disease and in 7 to lung cancer, while 5 represented primary cases. As controls we studied 28 individuals without HOA; of these, 12 were apparently healthy individuals, 7 had cyanosis secondary to chronic obstructive pulmonary disease, and 9 had lung cancer. ELISA was used to measure serum and plasma levels of VEGF.
RESULTS: Plasma levels of VEGF were significantly higher in the patients with primary HOA (median 46.2; range 19.4-398.8 pg/ml) and in those with lung cancer-HOA (median 75.5; range 24.6-166.7), compared to healthy controls (median 7.4; range: 0-26.1), p < 0.05. Serum VEGF levels were higher in patients with lung cancer and HOA (median 411.4; range 164.2-959.5 pg/ml) compared with lung cancer patients without HOA (median 74.5; range 13.2-205.4), p < 0.001.
CONCLUSIONS: Patients with primary HOA and those with HOA and lung cancer have increased circulating levels of VEGF. This cytokine may play a role in the pathogenesis of HOA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10728444

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  26 in total

1.  A case report of disabling bone pain after long-term kidney transplantation.

Authors:  T M M Myint; M Vucak-Dzumhur; P R Ebeling; G J Elder
Journal:  Osteoporos Int       Date:  2013-06-26       Impact factor: 4.507

Review 2.  Paraneoplastic syndromes associated with lung cancer.

Authors:  Nobuhiro Kanaji; Naoki Watanabe; Nobuyuki Kita; Shuji Bandoh; Akira Tadokoro; Tomoya Ishii; Hiroaki Dobashi; Takuya Matsunaga
Journal:  World J Clin Oncol       Date:  2014-08-10

3.  Hypertrophic osteoarthropathy presenting as unilateral cellulitis with successful treatment using pamidronate disodium.

Authors:  Sebastian G Bernardo; Jason J Emer; Mark E Burnett; Marsha Gordon
Journal:  J Clin Aesthet Dermatol       Date:  2012-09

4.  Treatment of hypertrophic osteoarthropathy in the case of pulmonary metastasis secondary-to-nasopharyngeal carcinoma with zoledronic acid: an enlightening experience.

Authors:  Nikhil Sonthalia; Kabita Mukherjee; Avishek Saha; Arunansu Talukdar
Journal:  BMJ Case Rep       Date:  2012-11-11

5.  [Tibial pain and unilateral knee arthritis: Precursors of paraneoplastic arthropathy].

Authors:  U Lange; G Bachmann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2011-06       Impact factor: 1.372

Review 6.  Paraneoplastic syndromes in rheumatology.

Authors:  Bernhard Manger; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

7.  Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy.

Authors:  Andrew C Johns; Chad Sorenson; Alan Rogers; Julia L Agne; Desmond M D'Souza; Jishu K Das; Majd Issa; Gina Perna; Terence M Williams; Alexa Meara; Trevor Kitchin; Karl E Haglund; Dwight H Owen
Journal:  Clin Lung Cancer       Date:  2020-01-27       Impact factor: 4.785

8.  Voriconazole Enhances the Osteogenic Activity of Human Osteoblasts In Vitro through a Fluoride-Independent Mechanism.

Authors:  Kahtonna C Allen; Carlos J Sanchez; Krista L Niece; Joseph C Wenke; Kevin S Akers
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

Review 9.  Primary hypertrophic osteoarthropathy: an update.

Authors:  Zeng Zhang; Changqing Zhang; Zhenlin Zhang
Journal:  Front Med       Date:  2013-01-23       Impact factor: 4.592

10.  A case of hypertrophic osteoarthropathy associated with epithelioid hemangioendothelioma.

Authors:  Jin Hyun Kim; Eun Bong Lee; Sunyoung Kim; Hyoun Woo Kang; Jung Won Suh; Won Jae Yoon; Su Hwan Kim; Eun Ha Kang; Churl Hyun Im; Yeong Wook Song; Hyo-Suk Lee
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.